On February 1, 2022 Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, reported that the executive management team will present and host meetings with investors at the virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February (Press release, Rubius Therapeutics, FEB 1, 2022, View Source [SID1234607568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update through fireside chats at Guggenheim Healthcare Talks | Idea Forum | Oncology Day on February 10, 2022, 08:00 a.m. EST and at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, 1:00 p.m. EST. Live audio webcasts for these events will be available within the Investors & Media section of the Rubius Therapeutics website. Archived replays will be accessible for 90 days following the events.